934388-20-2

Upstream product

• 64-17-5 ethanol 
• 102297-62-1 3-hydroxy-4-(1-oxo-ethane)benzoic acid 
• 108-24-7 acetic anhydride 
• 99-06-9 3-Carboxyphenol 
• 6304-89-8 3-acetoxybenzoic acid 

Downstream Products

• 934388-19-9 ethyl 4-acetyl-3-trifluoromethanesulfonyloxybenzoate 
• 191611-56-0 ethyl 2,2-dimethyl-4-oxochromane-7-carboxylate 
• 1393843-02-1 2-(2-chloro-6-fluorophenyl)-7-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,4-dimethyl-1,4-dihydro-chromeno[3,4-d]imidazole 
• 1393843-04-3 7-(1H-benzo[d]imidazol-2-yl)-2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-1,4-dihydrochromeno[3,4-d]imidazole 
• 1393843-20-3 2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-N-(4-methylthiazol-2-yl)-1,4-dihydrochromeno[3,4-d]imidazole-7-carboxamide 
• 1393843-05-4 2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-N-[4-(trifluoromethyl)phenyl]-1,4-dihydrochromeno[3,4-d]imidazole-7-carboxamide 
• 1393843-91-8 2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-1,4-dihydrochromeno[3,4-d]imidazole-7-carboxylic acid 
• 1393843-93-0 ethyl 2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-1,4-dihydrochromeno[3,4-d]imidazole-7-carboxylate 
• 1393844-52-4 N-(2-aminophenyl)-2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-1,4-dihydrochromeno[3,4-d]imidazole-7-carboxamide 
• 1242248-33-4 (E)-ethyl 4-(3-(4-(4-(4-chlorophenoxy)butoxy)phenyl)acryloyl)-3-hydroxybenzoate 

Relevant academic research and scientific papers

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

KINASE INHIBITORS

The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I, II, or III or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, I II III wherein X, R1, R2, R3, R31, n, and m have the meaning defined in the claims. In particular, the present invention relates more specifically to ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.